Gain Gross Profit Margin from 2010 to 2024

GANX Stock  USD 1.72  0.10  6.17%   
Gain Therapeutics Gross Profit Margin yearly trend continues to be fairly stable with very little volatility. Gross Profit Margin is likely to outpace its year average in 2024. During the period from 2010 to 2024, Gain Therapeutics Gross Profit Margin regression line of annual values had r-squared of  0.11 and arithmetic mean of (86.10). View All Fundamentals
 
Gross Profit Margin  
First Reported
2010-12-31
Previous Quarter
(205.22)
Current Value
(194.96)
Quarterly Volatility
50.93441538
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Gain Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gain Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 150 K, Net Interest Income of 579.3 K or Depreciation And Amortization of 44.3 K, as well as many indicators such as Price To Sales Ratio of 733, Dividend Yield of 0.0 or PTB Ratio of 3.55. Gain financial statements analysis is a perfect complement when working with Gain Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Gain Therapeutics Correlation against competitors.
For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.

Latest Gain Therapeutics' Gross Profit Margin Growth Pattern

Below is the plot of the Gross Profit Margin of Gain Therapeutics over the last few years. It is Gain Therapeutics' Gross Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Gain Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Gross Profit Margin10 Years Trend
Slightly volatile
   Gross Profit Margin   
       Timeline  

Gain Gross Profit Margin Regression Statistics

Arithmetic Mean(86.10)
Geometric Mean60.53
Coefficient Of Variation(59.16)
Mean Deviation30.40
Median(77.22)
Standard Deviation50.93
Sample Variance2,594
Range206
R-Value(0.33)
Mean Square Error2,483
R-Squared0.11
Significance0.22
Slope(3.80)
Total Sum of Squares36,320

Gain Gross Profit Margin History

2024 -194.96
2023 -205.22
2022 0.54
2021 -42.42

About Gain Therapeutics Financial Statements

Gain Therapeutics investors use historical fundamental indicators, such as Gain Therapeutics' Gross Profit Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Gain Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Gross Profit Margin(205.22)(194.96)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.